Study of controlled Shigella infection in Kenyan adults
Treatments studied
Part of Digestive system, Infections clinical trials.
This Phase 1 study gives a carefully measured dose of Shigella sonnei to healthy adults to learn about the infection’s safety and how the body responds. It may help researchers build safer future tests or treatments, but it requires a hospital stay and many follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 45 and live in Kilifi County
- Be generally healthy and pass the study understanding test (100%)
- Be able to stay in the hospital about 12+ days and then return for checkups for ~12 months
- Avoid certain medications and vaccines before and during the study (as instructed by the team)
- If you can become pregnant: use highly effective birth control for the entire study and not plan pregnancy during the study window
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a Shigella (gut infection) vaccine and additives to see how safe they are in healthy adults. If you qualify, you may help researchers understand whether the vaccine triggers any unwanted immune or stomach side effects.
This trial tests a new Shigella vaccine in healthy adults to see if it is safe and creates a good immune response. It is a first-in-human study, meaning this is the first time the vaccine is given to people.
This trial tests an oral vaccine designed to protect against two common causes of severe diarrhea: shigella and ETEC bacteria. Healthy adults aged 18 to 50 will receive the vaccine and later be exposed to the bacteria to see if it works.
This study tests how well a recommended treatment works for children aged 6 months to 5 years who have diarrhea caused by Shigella bacteria. It aims to find the best way to help children recover faster.
This trial tests a new vaccine called IP-QSV to see if it is safe and creates an immune response against Shigella bacteria, a common cause of diarrhea. It is for healthy adults, adolescents, children, and infants.
This study checks how long the altSonflex1-2-3 Shigella vaccine protects children, by looking at children who already received it in earlier studies about a year ago.
Hear when a new Shigellosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.